Christopher Ogden - Aug 10, 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Finance and Accounting
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol
CTMX
Transactions as of
Aug 10, 2022
Transactions value $
$0
Form type
4
Date filed
8/12/2022, 04:59 PM
Previous filing
Mar 9, 2022
Next filing
Feb 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +82.5K $0.00 82.5K Aug 10, 2022 Common Stock 82.5K $1.59 Direct F1
transaction CTMX Performance Stock Units (PSUs) Award $0 +13.8K $0.00 13.8K Aug 10, 2022 Common Stock 13.8K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F2 Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.